Menu
Search
|

Menu

Close
X

Aradigm Corp ARDM.OQ (NASDAQ Stock Exchange Capital Market)

1.30 USD
+0.03 (+2.36%)
As of Feb 16
chart
Previous Close 1.27
Open 1.35
Volume 23,857
3m Avg Volume 64,621
Today’s High 1.35
Today’s Low 1.27
52 Week High 7.26
52 Week Low 0.80
Shares Outstanding (mil) 15.15
Market Capitalization (mil) 19.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
12
FY16
0
FY15
23
EPS (USD)
FY17
-0.440
FY16
-2.229
FY15
-1.166
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
1.61
8.57
Price to Book (MRQ)
vs sector
--
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
--
15.12
LT Debt to Equity (MRQ)
vs sector
--
11.85
Return on Investment (TTM)
vs sector
-90.60
13.54
Return on Equity (TTM)
vs sector
--
14.80

EXECUTIVE LEADERSHIP

Virgil Thompson
Independent Chairman of the Board, Since 2005
Salary: --
Bonus: --
Igor Gonda
President, Chief Executive Officer, Director, Since 2006
Salary: $410,000.00
Bonus: --
Nancy Pecota
Chief Financial Officer, Vice President - Finance, Since 2008
Salary: $336,000.00
Bonus: --
Juergen Froehlich
Chief Medical Officer, Since 2013
Salary: $395,000.00
Bonus: --
David Bell
Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3929 Point Eden Way
HAYWARD   CA   94545-3720

Phone: +1510.2659000

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

SPONSORED STORIES